Home > Cardiology > HFA 2021 > HFA 2021 Highlights Podcast

HFA 2021 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
Conference
HFA 2021


 

In this episode, Medicom’s correspondent covers 6 presentations held at the Heart Failure Association and World Congress on Acute Heart Failure 2021, 29 June–1 July (HFA 2021). The topics discussed are:


    1. The IRON-CRT trial demonstrated that therapy with ferric carboxymaltose improved cardiac performance in intensively treated cardiac resynchronisation therapy patients with persistently reduced left ventricular ejection fraction.
    2. The GALACTIC-HF trial showed that heart failure patients with atrial fibrillation or flutter (AFF) at baseline had less treatment benefit from therapy with omecamtiv mecarbil than patients without AFF at baseline and that this effect was significantly more pronounced in patients treated with digoxin.
    3. CogTrain study: A twice-weekly cognitive training improved cognitive flexibility and working memory in patients with chronic heart failure. Cognitive training might emerge as a future heart failure intervention.
    4. According to a retrospective Portuguese study in breast cancer patients, lower BMI and treatment with trastuzumab alone or in combination were predictors of cardiotoxicity.
    5. Two trials on the efficacy of dapagliflozin in heart failure patients with preserved (HFpEF) and reduced (HFrEF) left ventricular function were not overall conclusive: DETERMINE-REDUCED & DETERMINE-PRESERVED.
    6. A Spanish study evaluated the possibility of amelioration in functional capacity through beta-blocker withdrawal in patients with heart failure with preserved ejection fraction (HFpEF). The results of the PRESERVE-HR trial confirmed a significant short-term improvement of the peak oxygen consumption (peakV02).

 

Copyright ©2021 Medicom Medical Publishers



Posted on